Id: acc0727
Group: 2sens
Protein: alpha-tubulin
Gene Symbol: TUBA1B
Protein Id: P68363
Protein Name: TBA1B_HUMAN
PTM: acetylation
Site: lys
Site Sequence:
Disease Category: Cancer
Disease: Breast Cancer
Disease Subtype:
Disease Cellline: SK-BR-3
Disease Info:
Drug: geldanamycin
Drug Info: "Geldanamycin is a naturally occurring benzoquinone ansamycin antibiotic that inhibits the activity of heat shock protein 90 (Hsp90), primarily used in research for its potential anticancer properties."
Effect: enhance
Effect Info: "CBZ treatment induces an increase in Hsp90 acetylation and alpha-tubulin acetylation by inhibiting HDAC, leading to the dissociation of Her-2 from Hsp90 and the entry of Her-2 into ubiquitin-mediated degradation, and inhibits the proliferation of breast cancer cells."
Note:
Score: 5.0
Pubmed(PMID): 21082217
Sentence Index:
Sentence:

Sequence & Structure:

MRECISIHVGQAGVQIGNACWELYCLEHGIQPDGQMPSDKTIGGGDDSFNTFFSETGAGKHVPRAVFVDLEPTVIDEVRTGTYRQLFHPEQLITGKEDAANNYARGHYTIGKEIIDLVLDRIRKLADQCTGLQGFLVFHSFGGGTGSGFTSLLMERLSVDYGKKSKLEFSIYPAPQVSTAVVEPYNSILTTHTTLEHSDCAFMVDNEAIYDICRRNLDIERPTYTNLNRLISQIVSSITASLRFDGALNVDLTEFQTNLVPYPRIHFPLATYAPVISAEKAYHEQLSVAEITNACFEPANQMVKCDPRHGKYMACCLLYRGDVVPKDVNAAIATIKTKRSIQFVDWCPTGFKVGINYQPPTVVPGGDLAKVQRAVCMLSNTTAIAEAWARLDHKFDLMYAKRAFVHWYVGEGMEEGEFSEAREDMAALEKDYEEVGVDSVEGEGEEEGEEY

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
TUBA1B MIRVETUXIMAB SORAVTANSINE Tubulin inhibitor 4 - peritoneal neoplasm FDA
TUBA1B MIRVETUXIMAB SORAVTANSINE Tubulin inhibitor 4 - malignant epithelial tumor of ovary FDA
TUBA1B MIRVETUXIMAB SORAVTANSINE Tubulin inhibitor 4 - fallopian tube neoplasm FDA
TUBA1B VINFLUNINE Tubulin inhibitor 3 Completed bladder tumor ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 - neoplasm ATC
TUBA1B VINFLUNINE Tubulin inhibitor 3 - neoplasm ATC
TUBA1B OMBRABULIN Tubulin inhibitor 3 Completed sarcoma ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 Terminated non-small cell lung carcinoma ClinicalTrials
TUBA1B PLINABULIN Tubulin inhibitor 3 Completed non-small cell lung carcinoma ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 Unknown status ovarian serous adenocarcinoma ClinicalTrials
TUBA1B TUSAMITAMAB RAVTANSINE Tubulin inhibitor 3 Active, not recruiting non-small cell lung carcinoma ClinicalTrials
TUBA1B VINFLUNINE Tubulin inhibitor 3 Active, not recruiting urogenital neoplasm ClinicalTrials
TUBA1B VINFLUNINE Tubulin inhibitor 3 Completed urogenital neoplasm ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 Unknown status undifferentiated carcinoma ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 Unknown status ovarian mucinous adenocarcinoma ClinicalTrials
TUBA1B VINFLUNINE Tubulin inhibitor 3 Completed urothelial carcinoma ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 Unknown status ovarian clear cell adenocarcinoma ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 Unknown status Primary Peritoneal Serous Adenocarcinoma ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 Unknown status Fallopian Tube Serous Adenocarcinoma ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 Unknown status Ovarian Transitional Cell Carcinoma ClinicalTrials
TUBA1B PACLITAXEL POLIGLUMEX Tubulin stabiliser 3 Unknown status Malignant Ovarian Brenner Tumor ClinicalTrials
TUBA1B VINFLUNINE Tubulin inhibitor 3 Completed urinary bladder cancer ClinicalTrials
ClinicalTrials
TUBA1B PLINABULIN Tubulin inhibitor 3 Completed neutropenia ClinicalTrials
TUBA1B PLINABULIN Tubulin inhibitor 3 Active, not recruiting neutropenia ClinicalTrials
TUBA1B VINFLUNINE Tubulin inhibitor 3 Completed head and neck carcinoma ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: